オレンシア（アバタセプト）の世界市場レポート 2025年：疫学、パイプライン分析、市場インサイトと予測

オレンシア（アバタセプト）の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR12%で47億3,350万米ドルまで拡大します。この予測期間における成長は、個別化医療の採用の増加、侵襲の少ない皮下投与に対する患者の嗜好の高まり、医療アクセスが向上している新興市場での拡大、優れた有効性と安全性プロファイルによる生物製剤へのシフトの進行などに起因すると考えられます。予測期間における主要動向としては、先進国市場における償還シナリオの改善、バイオシミラーや費用対効果の高い代替品へのシフト、提携、製品承認などが挙げられます。

自己免疫疾患の有病率の増加は、今後のオレンシア（アバタセプト）市場の成長を牽引すると予想されます。自己免疫疾患は、免疫系が誤って体内の細胞や組織、臓器を攻撃し、炎症や損傷を引き起こすことで発症します。これは関節リウマチや多発性硬化症のような慢性疾患につながるが、その原因は遺伝的要因と環境的要因の両方に根ざしています。自己免疫疾患の増加は、遺伝的素因、環境的誘因、より多くの症例が特定されるようになった認識と診断の向上などの要因によるものです。オレンシア（アバタセプト）は、選択的T細胞コスト刺激阻害によって免疫反応を調節し、炎症を抑えて免疫系が健康な組織を攻撃するのを防ぐことにより、自己免疫疾患の管理を助ける。例えば、2024年3月、米国の非営利団体であるNational Health Councilは、自己免疫疾患は約5,000万人の米国人を罹患させ、その症例は毎年3～12％増加していると報告しました。世界的に見ると、多発性硬化症の症例は2022年には前の10年と比較して30％増加しました。その結果、自己免疫疾患の有病率の増加がオレンシア（アバタセプト）市場の成長に寄与しています。

個別化医療の台頭がオレンシア（アバタセプト）市場の成長を促進すると予想されます。個別化医療とは、最も正確で効果的な結果を得るために、治療やヘルスケア戦略を個人特有の遺伝的体質、環境、ライフスタイルに合わせて調整することです。個別化医療の成長は、ゲノム技術の進歩、分子生物学に対するより深い理解、精密診断ツールの利用可能性の増加、副作用を抑えつつ患者の転帰を改善する標的治療に対する需要によってもたらされます。オレンシア（アバタセプト）は、自己免疫疾患に関与する特定の免疫系経路を標的とすることで個別化医療の一翼を担い、全身的な副作用を最小限に抑え、患者固有の免疫反応や疾患特性に基づいて治療結果を最適化するカスタマイズ型治療計画を可能にします。例えば、米国を拠点とする団体である個別化医療連合（Personalized Medicine Coalition）は2023年、2022年にはFDAが新薬の34%で個別化医療を承認し、それ以前の8年間では新薬の少なくとも25%が個別化治療の承認を受けたと報告しています。したがって、個別化医療の台頭がオレンシア（アバタセプト）市場を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症、景気回復が市場に与える影響を含むマクロ経済シナリオ

第6章 世界の成長分析と戦略分析フレームワーク

• 世界のオレンシア（アバタセプト）：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のオレンシア（アバタセプト）市場：成長率分析
• 世界のオレンシア（アバタセプト）市場の実績：規模と成長、2019～2024年
• 世界のオレンシア（アバタセプト）市場の予測：規模と成長、2024～2029年、2034年
• 世界のオレンシア（アバタセプト）：総潜在市場規模（TAM）

第7章 世界市場の価格分析と予測

第8章 市場セグメンテーション

• 世界のオレンシア（アバタセプト）市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• プレフィルドシリンジ
• バイアル
• 世界のオレンシア（アバタセプト）市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 関節リウマチ
• 若年性特発性関節炎
• 乾癬性関節炎
• 世界のオレンシア（アバタセプト）市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局

第9章 臨床適応症の世界市場疫学

• 薬剤の副作用
• 臨床適応症の発症率と有病率

第10章 地域別・国別分析

• 世界のオレンシア（アバタセプト）市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のオレンシア（アバタセプト）市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• オレンシア（アバタセプト）市場：競合情勢
• オレンシア（アバタセプト）市場：企業プロファイル
  • Bristol-Myers Squibb（BMS）

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、戦略

• オレンシア（アバタセプト）市場、2029年：新たな機会を提供する国
• オレンシア（アバタセプト）市場、2029年：新たな機会を提供するセグメント
• オレンシア（アバタセプト）市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第34章 付録

Orencia (abatacept) is a prescription medication used to treat certain autoimmune diseases. It is classified as a selective T-cell co-stimulation modulator, which works by suppressing overactive immune responses that cause inflammation and tissue damage.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The key formulations of orencia (abatacept) include prefilled syringes and vials. A prefilled syringe contains a single dose of the medication and is used to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis. These formulations are used for various applications, including rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis, and are distributed through different channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The orencia (abatacept) market research report is one of a series of new reports from The Business Research Company that provides orencia (abatacept) market statistics, including orencia (abatacept) industry global market size, regional shares, competitors with a orencia (abatacept) market share, detailed orencia (abatacept) market segments, market trends and opportunities, and any further data you may need to thrive in the orencia (abatacept) industry. This orencia (abatacept) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The orencia (abatacept) market size is expected to see rapid growth in the next few years. It will grow to $4,733.5 million in 2029 at a compound annual growth rate (CAGR) of 12%. The growth in the forecast period can be attributed to increasing adoption of personalized medicine, growing patient preference for less invasive subcutaneous administration, expansion in emerging markets with rising healthcare access, the ongoing shift toward biologic therapies due to their superior efficacy and safety profiles. Major trends in the forecast period include improving reimbursement scenarios in developed markets, a shift towards biosimilars and cost-effective alternatives, partnerships, product approvals.

The increasing prevalence of autoimmune disorders is expected to drive the growth of the orencia (abatacept) market in the future. Autoimmune disorders occur when the immune system mistakenly attacks the body's own cells, tissues, or organs, resulting in inflammation and damage. This leads to chronic conditions like rheumatoid arthritis and multiple sclerosis, which have causes rooted in both genetic and environmental factors. The rise in autoimmune disorders is attributed to factors such as genetic predisposition, environmental triggers, and greater awareness and diagnosis, leading to more cases being identified. Orencia (abatacept) aids in managing autoimmune diseases by modulating the immune response through selective T-cell costimulation inhibition, thus reducing inflammation and preventing the immune system from attacking healthy tissues. For example, in March 2024, the National Health Council, a U.S.-based non-profit organization, reported that autoimmune diseases affect approximately 50 million Americans, with cases increasing by 3-12% annually. Globally, multiple sclerosis cases rose by 30% in 2022 compared to the previous decade. As a result, the increasing prevalence of autoimmune disorders is contributing to the growth of the orencia (abatacept) market.

The rise of personalized medicine is expected to fuel the growth of the orencia (abatacept) market. Personalized medicine involves tailoring treatment and healthcare strategies to an individual's unique genetic makeup, environment, and lifestyle to achieve the most precise and effective outcomes. The growth of personalized medicine is driven by advancements in genomic technologies, a better understanding of molecular biology, the increased availability of precision diagnostic tools, and the demand for targeted therapies that improve patient outcomes while reducing side effects. Orencia (abatacept) plays a role in personalized medicine by targeting specific immune system pathways involved in autoimmune diseases, allowing for customized treatment plans that minimize systemic side effects and optimize therapeutic results based on a patient's unique immune response and disease characteristics. For example, in 2023, the Personalized Medicine Coalition, a U.S.-based organization, reported that in 2022, the FDA approved personalized medicines for 34% of new drugs, and over the prior eight years, at least 25% of new drugs had received approval for personalized treatment. Therefore, the rise of personalized medicine is driving the orencia (abatacept) market.

A key trend in the orencia (abatacept) market is the focus on developing innovative drugs to enhance treatment effectiveness, improve patient outcomes, and address unmet needs in managing autoimmune diseases. Abatacept is a biologic medication used in the treatment of juvenile psoriatic arthritis (JPsA), a rare autoimmune condition affecting children and adolescents, causing joint inflammation and skin lesions. For example, in October 2023, Bristol Myers Squibb, a U.S.-based pharmaceutical company, announced that the FDA approved the Biologics Licensing Application (sBLA) for abatacept (Orencia) to treat juvenile psoriatic arthritis (JPsA) in patients aged 2 to 17 years. This approval was based on controlled studies involving both adults and children, utilizing pharmacokinetic data from studies on adults with rheumatoid arthritis and psoriatic arthritis, as well as safety data from clinical trials involving children aged 2 to 17 years with polyarticular juvenile idiopathic arthritis (JIA).

Key player operating in the orencia (abatacept) market is Bristol-Myers Squibb (BMS).

North America was the largest region in the orencia (abatacept) market in 2024. The regions covered in orencia (abatacept) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the orencia (abatacept) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The orencia market consists of sales of abatacept-based biologic therapies, injectable and intravenous solutions, and immunomodulatory treatments. Values in this market are 'factory gate' values, which represent the value of goods sold by the manufacturers or creators of the goods, whether to other entities (such as wholesalers, distributors, and healthcare providers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Orencia (Abatacept) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on orencia (abatacept) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for orencia (abatacept) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The orencia (abatacept) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Prefilled Syringe; Vial
• 2) By Application: Rheumatoid Arthritis; Juvenile Idiopathic Arthritis; Psoriatic Arthritis
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: Bristol-Myers Squibb (BMS)
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Orencia (Abatacept) Market Characteristics

3. Orencia (Abatacept) Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Orencia (Abatacept) Market Trends And Strategies

5. Orencia (Abatacept) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Orencia (Abatacept) Growth Analysis And Strategic Analysis Framework

• 6.1. Global Orencia (Abatacept) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Orencia (Abatacept) Market Growth Rate Analysis
• 6.4. Global Orencia (Abatacept) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Orencia (Abatacept) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Orencia (Abatacept) Total Addressable Market (TAM)

7. Global Orencia (Abatacept) Market Pricing Analysis & Forecasts

8. Orencia (Abatacept) Market Segmentation

• 8.1. Global Orencia (Abatacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prefilled Syringe
• Vial
• 8.2. Global Orencia (Abatacept) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rheumatoid Arthritis
• Juvenile Idiopathic Arthritis
• Psoriatic Arthritis
• 8.3. Global Orencia (Abatacept) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

9. Global Orencia (Abatacept) Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Orencia (Abatacept) Market Regional And Country Analysis

• 10.1. Global Orencia (Abatacept) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Orencia (Abatacept) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Orencia (Abatacept) Market

• 11.1. Asia-Pacific Orencia (Abatacept) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Orencia (Abatacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Orencia (Abatacept) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Orencia (Abatacept) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Orencia (Abatacept) Market

• 12.1. China Orencia (Abatacept) Market Overview
• 12.2. China Orencia (Abatacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Orencia (Abatacept) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Orencia (Abatacept) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Orencia (Abatacept) Market

• 13.1. India Orencia (Abatacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Orencia (Abatacept) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Orencia (Abatacept) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Orencia (Abatacept) Market

• 14.1. Japan Orencia (Abatacept) Market Overview
• 14.2. Japan Orencia (Abatacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Orencia (Abatacept) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Orencia (Abatacept) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Orencia (Abatacept) Market

• 15.1. Australia Orencia (Abatacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Orencia (Abatacept) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Orencia (Abatacept) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Orencia (Abatacept) Market

• 16.1. South Korea Orencia (Abatacept) Market Overview
• 16.2. South Korea Orencia (Abatacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Orencia (Abatacept) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Orencia (Abatacept) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Orencia (Abatacept) Market

• 17.1. Western Europe Orencia (Abatacept) Market Overview
• 17.2. Western Europe Orencia (Abatacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Orencia (Abatacept) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Orencia (Abatacept) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Orencia (Abatacept) Market

• 18.1. UK Orencia (Abatacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Orencia (Abatacept) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Orencia (Abatacept) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Orencia (Abatacept) Market

• 19.1. Germany Orencia (Abatacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Orencia (Abatacept) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Orencia (Abatacept) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Orencia (Abatacept) Market

• 20.1. France Orencia (Abatacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Orencia (Abatacept) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Orencia (Abatacept) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Orencia (Abatacept) Market

• 21.1. Eastern Europe Orencia (Abatacept) Market Overview
• 21.2. Eastern Europe Orencia (Abatacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Orencia (Abatacept) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Orencia (Abatacept) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Orencia (Abatacept) Market

• 22.1. North America Orencia (Abatacept) Market Overview
• 22.2. North America Orencia (Abatacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Orencia (Abatacept) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Orencia (Abatacept) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Orencia (Abatacept) Market

• 23.1. USA Orencia (Abatacept) Market Overview
• 23.2. USA Orencia (Abatacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Orencia (Abatacept) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Orencia (Abatacept) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Orencia (Abatacept) Market

• 24.1. Canada Orencia (Abatacept) Market Overview
• 24.2. Canada Orencia (Abatacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Orencia (Abatacept) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Orencia (Abatacept) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Orencia (Abatacept) Market

• 25.1. South America Orencia (Abatacept) Market Overview
• 25.2. South America Orencia (Abatacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Orencia (Abatacept) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Orencia (Abatacept) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Orencia (Abatacept) Market

• 26.1. Middle East Orencia (Abatacept) Market Overview
• 26.2. Middle East Orencia (Abatacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Orencia (Abatacept) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Orencia (Abatacept) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Orencia (Abatacept) Market

• 27.1. Africa Orencia (Abatacept) Market Overview
• 27.2. Africa Orencia (Abatacept) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Orencia (Abatacept) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Orencia (Abatacept) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Orencia (Abatacept) Market Competitive Landscape And Company Profiles

• 28.1. Orencia (Abatacept) Market Competitive Landscape
• 28.2. Orencia (Abatacept) Market Company Profiles
  • 28.2.1. Bristol-Myers Squibb (BMS) Overview, Products and Services, Strategy and Financial Analysis

29. Global Orencia (Abatacept) Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Orencia (Abatacept) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Orencia (Abatacept) Market

32. Recent Developments In The Orencia (Abatacept) Market

33. Orencia (Abatacept) Market High Potential Countries, Segments and Strategies

• 33.1 Orencia (Abatacept) Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Orencia (Abatacept) Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Orencia (Abatacept) Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer